Unknown

Dataset Information

Healthcare resource utilization in patients treated with empagliflozin in East Asia.


ABSTRACT:

Aims/introduction

We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, versus dipeptidyl peptidase-4 (DPP-4) inhibitors in clinical practice in Japan, South Korea, and Taiwan.

Materials and methods

We analyzed the Japanese Medical Data Vision database (December 2014-April 2018), the South Korean National Health Information Database, and the Taiwanese National Health Insurance claims database (both May 2016-December 2017). Patients with type 2 diabetes starting empagliflozin, 10 or 25 mg, or a DPP-4 inhibitor were matched 1:1 via propensity scores (PS). We compared inpatient care needs, emergency room (ER) visits, and outpatient visits between the treatment gro

SUBMITTER: Sheu WH 

PROVIDER: S-EPMC9077718 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature